Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

Background Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT). Subgroup analyses demonstrated that pts with low volume (LV), per CHAARTED trial definition,...

Full description

Saved in:

Bibliographic Details
Published in:	The Prostate Vol. 78; no. 12; pp. 889 - 895
Main Authors:	Francini, Edoardo, Gray, Kathryn P., Xie, Wanling, Shaw, Grace K., Valença, Loana, Bernard, Brandon, Albiges, Laurence, Harshman, Lauren C., Kantoff, Philip W., Taplin, Mary‐Ellen, Sweeney, Cristopher J.
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01.09.2018
Subjects:	ADT Aged Androgen Antagonists - administration & dosage Androgen Antagonists - therapeutic use Antineoplastic Agents Castration Classification Docetaxel - therapeutic use Humans Male Medical prognosis Metastases Metastasis mHSPC Middle Aged Neoplasm Metastasis - pathology Pain Prognosis prognostic classification Proportional Hazards Models Prostate cancer Prostate-Specific Antigen - analysis Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy Prostatic Neoplasms, Castration-Resistant Registries Retrospective Studies Survival Rate Time Factors time of metastatic disease volume of disease volume of disease ADT prognostic classification mHSPC time of metastatic disease
ISSN:	0270-4137, 1097-0045, 1097-0045
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!